OSI Systems (OSIS) Q4 2026 earnings review
Earnings Surge Masks Top-Line Contraction as Cash Flow Finally Arrives
OSI Systems missed Q4 revenue growth expectations, reporting a 4% year-over-year decline to $484M due to delivery pushouts in the Middle East. However, exceptional margin execution and a massive cash flow rebound saved the quarter. Record Non-GAAP EPS grew 17% to $3.78, fueled by a dramatic turnaround in Healthcare profitability and solid execution in Optoelectronics. The long-awaited collection of delayed receivables materialized, generating a record $182M in operating cash flow. While the top-line hiccup is concerning, management framed it as a timing issue, pointing to a resilient $1.9B backlog and initiating solid FY27 guidance of 5-8% top-line growth.
🐂 Bull Case
The company finally monetized its massive receivables pile, printing $182M in operating cash flow in Q4 alone, allowing for aggressive $123M share repurchases.
Despite lower volumes in Security, consolidated profitability surged. Healthcare was the standout, flipping from a 0.9% margin a year ago to 10.0% this quarter.
🐻 Bear Case
The Middle East conflict actively suppressed Security revenues this quarter. If unrest continues, 'timing shifts' could turn into prolonged stagnant capital.
Q4 marked a reversal from the double-digit revenue growth seen in H1 2026, dropping to -4%. The company is highly reliant on lumpy, large-scale deployments.
⚖️ Verdict: 🟢
Bullish. While the revenue contraction is optically poor, the underlying business is extremely healthy. The company proved it can expand margins during a revenue dip, collected the cash it promised, and aggressively bought back stock. The $1.9B backlog heavily de-risks FY27.
Key Themes
Historic Operating Cash Flow Surge
After quarters of scrutiny regarding a massive uncollected accounts receivable balance (largely tied to Mexico contracts), the dam broke in Q4. OSI generated a record $182.1M in operating cash flow, compared to a paltry $0.5M in the prior-year period. Full-year operating cash flow hit $275.9M. This proves management's prior claims that the AR issue was strictly timing, not a structural collection failure.
Healthcare Profitability Turnaround
The Healthcare division flipped from being a margin laggard to a major bottom-line contributor. Non-GAAP operating margin accelerated to 10.0% from just 0.9% in 25Q4 and 1.3% in 26Q3. While revenue growth was a modest 5%, the operational improvements implemented throughout the year have finally taken root, dramatically lifting the segment's earnings power.
Revenue Contraction Contradicts EPS Narrative
Management hailed fiscal 2026 as a 'strong year' capped by 'record fourth quarter non-GAAP earnings.' However, this bottom-line success masks a reversing top-line trend: consolidated revenue actually fell 4% YoY to $484M. This specifically contradicts the growth narrative built in the first half of the year, showing that external shocks are overriding operational execution at the revenue line.
Middle East Conflict Disrupts Security Segment
A clear macro headwind impacted the core business: conflicts in the Middle East forced the delay of planned deliveries. As a result, Security division revenues reversed, dropping 7.4% YoY to $339.7M. While management insists these are delayed schedules and not cancellations, geopolitical volatility remains a persistent threat to quarterly run rates.
Optoelectronics Thriving on Supply Chain De-Risking
The Optoelectronics & Manufacturing segment continues to be a quiet powerhouse, growing revenues 5% to $117.8M with a 14.7% operating margin. The division remains a prime beneficiary of the global macro trend of OEMs diversifying their supply chains and precision manufacturing away from China toward nearshore and allied global footprints.
Accounts Receivable Overhang Persists
Despite the phenomenal Q4 cash collection, total net Accounts Receivable remains highly elevated at $764.6M (down less than 9% from $837.7M a year ago). While the trajectory is finally moving in the right direction, this massive balance continues to tie up significant working capital and poses a concentration risk.
Aggressive Capital Return Strategy
OSI Systems used its freshly unlocked cash flow to aggressively buy back stock, retiring 564,880 shares for $123.6M in Q4 alone. Furthermore, the Board authorized an additional 1,000,000 shares for repurchase. With bank lines of credit reduced to zero, management is clearly pivoting capital allocation toward equity reduction rather than debt service.
Expanding High-Engineered Patient and Security Solutions
The company's technology initiatives are anchoring its margin expansion. Management explicitly highlighted advancing product development in 'patient monitoring and diagnostic cardiology' as the bedrock of the Healthcare segment turnaround, shifting the mix toward higher-margin, innovative clinical solutions rather than commoditized hardware.
Other KPIs
Stable quarter-over-quarter and up from $1.8 billion a year ago. The sheer size of this backlog provides massive visibility and buffers the company against short-term booking delays caused by geopolitical conflicts or US government continuing resolutions.
Accelerated from 20.4% in 25Q4 and 18.3% in 26Q3. The ability to expand margins by 40 basis points year-over-year despite a 7.4% revenue decline in the segment is a testament to strong cost controls and a higher-margin product/service mix.
Guidance
Accelerating. The midpoint of $1.902B implies a 6.5% YoY growth rate. This signals confidence that the Q4 top-line contraction (-4%) was an anomaly and that delayed Middle East orders will convert to revenue in the coming fiscal year.
Decelerating but strong. The midpoint of $11.31 implies 9.2% YoY growth. While slower than the 11% growth achieved in FY26, this guidance is likely conservative given the massive share repurchase authorization which artificially boosts EPS.
Key Questions
Middle East Delivery Timelines
You cited Middle East conflicts as the primary driver for delayed security deliveries. What is the specific timeline for recognizing this revenue, and is it fully baked into the 5-8% top-line growth guidance for FY27?
Healthcare Margin Sustainability
Healthcare margins exploded to 10% in Q4 from low single digits. Is this 10% run-rate the new normal for the division, or were there one-time mix benefits in the quarter?
Accounts Receivable Glide Path
While operating cash flow was stellar in Q4, total AR remains elevated at $764M. What is the target AR balance by the end of FY27, and how much of the remaining balance is tied to the legacy Mexico contracts?
Capital Allocation Hierarchy
With the credit facility drawn down to zero and a new 1M share repurchase authorization, how does M&A fit into the near-term strategy versus aggressively buying back the stock?